266 related articles for article (PubMed ID: 19737884)
1. Trichostatin A-induced TGF-beta type II receptor expression in retinoblastoma cell lines.
Kashiwagi Y; Horie K; Kanno C; Inomata M; Imamura T; Kato M; Yamamoto T; Yamashita H
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):679-85. PubMed ID: 19737884
[TBL] [Abstract][Full Text] [Related]
2. Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.
Horie K; Yamashita H; Mogi A; Takenoshita S; Miyazono K
J Cell Physiol; 1998 Jun; 175(3):305-13. PubMed ID: 9572475
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines.
Osada H; Tatematsu Y; Masuda A; Saito T; Sugiyama M; Yanagisawa K; Takahashi T
Cancer Res; 2001 Nov; 61(22):8331-9. PubMed ID: 11719467
[TBL] [Abstract][Full Text] [Related]
4. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells.
Zhao S; Venkatasubbarao K; Li S; Freeman JW
Cancer Res; 2003 May; 63(10):2624-30. PubMed ID: 12750289
[TBL] [Abstract][Full Text] [Related]
5. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
Lee BI; Park SH; Kim JW; Sausville EA; Kim HT; Nakanishi O; Trepel JB; Kim SJ
Cancer Res; 2001 Feb; 61(3):931-4. PubMed ID: 11221885
[TBL] [Abstract][Full Text] [Related]
6. Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines.
Osada H; Tatematsu Y; Sugito N; Horio Y; Takahashi T
Mol Carcinog; 2005 Dec; 44(4):233-41. PubMed ID: 16163707
[TBL] [Abstract][Full Text] [Related]
7. Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activity.
Klan N; Seuter S; Schnur N; Jung M; Steinhilber D
Biol Chem; 2003 May; 384(5):777-85. PubMed ID: 12817474
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of TGF-beta cell surface receptors during progression of human oral squamous cell carcinoma.
Paterson IC; Matthews JB; Huntley S; Robinson CM; Fahey M; Parkinson EK; Prime SS
J Pathol; 2001 Apr; 193(4):458-67. PubMed ID: 11276004
[TBL] [Abstract][Full Text] [Related]
9. miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-β type II receptor.
Wang H; Liu J; Zong Y; Xu Y; Deng W; Zhu H; Liu Y; Ma C; Huang L; Zhang L; Qin C
Brain Res; 2010 Oct; 1357():166-74. PubMed ID: 20709030
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
Guo Y; Kyprianou N
Cell Growth Differ; 1998 Feb; 9(2):185-93. PubMed ID: 9486855
[TBL] [Abstract][Full Text] [Related]
11. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells.
Lu S; Dong Z
Prostate; 2006 Jun; 66(9):996-1004. PubMed ID: 16541418
[TBL] [Abstract][Full Text] [Related]
12. Deletion of one adenine base within the polyadenine tract of transforming growth factor-beta receptor type II in human MDA-MB-231 breast cancer cell line.
Park B; Jang JS; Park K
Int J Oncol; 2000 Sep; 17(3):473-8. PubMed ID: 10938386
[TBL] [Abstract][Full Text] [Related]
13. Glioma gene therapy with soluble transforming growth factor-beta receptors II and III.
Naumann U; Maass P; Gleske AK; Aulwurm S; Weller M; Eisele G
Int J Oncol; 2008 Oct; 33(4):759-65. PubMed ID: 18813789
[TBL] [Abstract][Full Text] [Related]
14. Loss of functional transforming growth factor (TGF)-beta type II receptor results in insensitivity to TGF-beta1-mediated apoptosis and Epstein-Barr virus reactivation.
Fukuda M; Kurosaki H; Sairenji T
J Med Virol; 2006 Nov; 78(11):1456-64. PubMed ID: 16998876
[TBL] [Abstract][Full Text] [Related]
15. Sequence-specific enhancer binding protein is responsible for the differential expression of ERT/ESX/ELF-3/ESE-1/jen gene in human gastric cancer cell lines: Implication for the loss of TGF-beta type II receptor expression.
Park SH; Kim YS; Park BK; Hougaard S; Kim SJ
Oncogene; 2001 Mar; 20(10):1235-45. PubMed ID: 11313868
[TBL] [Abstract][Full Text] [Related]
16. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
17. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of the murine type II transforming growth factor-beta receptor promoter by the transcription factor Egr-1.
Wilder PJ; Bernadt CT; Kim JH; Rizzino A
Mol Reprod Dev; 2002 Nov; 63(3):282-90. PubMed ID: 12237943
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of induction of transforming growth factor-beta type II receptor gene expression by v-Src in murine myeloid cells.
Park SH; Birchenall-Roberts MC; Yi Y; Lee BI; Lee DK; Bertolette DC; Fu T; Ruscetti F; Kim SJ
Cell Growth Differ; 2001 Jan; 12(1):9-18. PubMed ID: 11205746
[TBL] [Abstract][Full Text] [Related]
20. Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Muro-Cacho CA; Rosario-Ortiz K; Livingston S; Muñoz-Antonia T
Clin Cancer Res; 2001 Jun; 7(6):1618-26. PubMed ID: 11410498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
